GlassScriptPhysician profile
Ashley Nichole Simon
NPI 1851053565
$4,176.54
in general payments reported to CMS, 2019-2025
22 companies · $43.85 in 2025
The $43.85 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $677 · 2023: $2,131 · 2024: $1,324 · 2025: $43.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,499.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $654.30 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $634.73 | 2022-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $432.30 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Vanda Pharmaceuticals INC. | $262.38 | 2022-2024 | Fanapt, Hetlioz |
| Corium, LLC | $256.91 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $238.08 | 2022-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $235.86 | 2022-2024 | Nuedexta, Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $229.54 | 2022-2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $142.57 | 2022-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $142.10 | 2023-2024 | Trintellix |
| Tris Pharma INC | $134.94 | 2023-2024 | Dyanavel Xr |
| Alkermes, INC. | $110.62 | 2022-2023 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $109.67 | 2022-2023 | Ingrezza |
| Almatica Pharma LLC | $108.10 | 2023-2024 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $103.85 | 2022-2024 | Spravato, Invega Sustenna, Invega Trinza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $87.39 | 2022-2024 | Perseris |
| Neos Therapeutics, LP | $84.19 | 2023-2024 | Adzenys Xr-Odt |
| Lundbeck LLC | $70.67 | 2023-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $67.50 | 2023 | Belsomra |
| Livanova USA, INC. | $26.52 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Noven Therapeutics, LLC | $22.34 | 2023 | Secuado, Xelstrym |
| Biogen, INC. | $21.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.